Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
Yajun Shu Zhuoqun Sun Fan Gao Zhuhang Huang Xing Meng Shaomin Chen Qun Shu Lianhao Wang Hengming Zhang Zhifang Ying Jikai Zhang a Department of Biological Products Monitoring and Evaluation,Guangdong Provincial Institute of Biological Products and Materia Medica,Guangzhou,Chinab Department of Clinical Research and Development,Sinovac Life Sciences Co.,Ltd,Beijing,Chinac Division of Vaccines,National Institutes for Food and Drug Control,Beijing,Chinad Department of Clinical Research and Development,Sinovac Biotech Co.,Ltd,Beijing,Chinae Department of Statistics Sciences,Beijing KeyTech Statistical Consulting Co.,Ltd,Beijing,ChinaYajun Shu,Master of Pharmacy,has engaged in drug clinical trials and undertook 7 vaccine clinical trials as coordinating investigator for nearly 10 years. Shu paparticipated in multiple scientific research projects and published 5 articles as the first author.Zhuoqun Sun received her Master's degree in Internal Medicine from Peking University in 2022. Her research interests encompass HIV treatment and epidemiology. Following graduation,she joined Sinovac Life Sciences Co.,Ltd. as a clinical research physician,where she is responsible for the clinical development of vaccines and bio-products. She has participated in the medical aspects of over 5 clinical trials,ranging from Phase I to Phase IV.Fan Gao,a professor,mainly focus is on conducting quality assessments for viral hepatitis,hand,foot and mouth disease,as well as COVID-19 vaccines. As a technical researcher,he has actively participated in and successfully completed numerous national "12th Five-Year","13th Five-Year" major special projects,and National High Technology Research and Development Program ("863" program) projects.Zhuhang Huang,M. D.,Guangdong pharmaceutical registration licensing expert,Guangdong Pharmaceutical Association Medical Clinical Trial Professional Committee member,Guangdong Pharmaceutical University graduate practice tutor. As the Principal Investigator,Huang undertook three clinical trials of registered vaccines,and participated in the construction of State Food and Drug Administration Laboratories,Provincial Science and Technology Department,Provincial Development and Reform Commission,Provincial Drug Administration,Municipal Science and Information Bureau and other scientific research platforms or key laboratory platform,and published 10 articles as a corresponding author or first author.Xing Meng received the B.S. degree in Biotechnology from Nankai University,China in 2011,and received the Ph.D. degree in Biotechnology from Peking University,China in 2016. Her research interests during Ph.D. were mechanism study and application of small RNA. She has been working in GlaxoSmithKline and Tsinghua University during 2017 to 2019 as a Clinical post-doc fellow,working on epidemiologic studies and clinical development programs for new drugs. She's working in Sinovac Biotech Co.,Ltd.,as a medical manager since 2019,focus on clinical development of vaccines/bio-products. She has leaded or participated in the medical work of more than 20 clinical trials,and been responsible for overall medical and safety oversight of more than 8 products.Shaomin Chen,Master of Science,mainly engages in vaccine clinical trials,served as coordinating investigator for 5 registered vaccine clinical trials. Chen has published 2 articles as the first author since starting work.Qun Shu,Statistical Manager. She has extensive experience in clinical trial protocol design and statistical analysis. During her 5 years of work,she has leaded or participated in the statistics work of more than 50 clinical trials of vaccines and drugs,including phase I to phase IV trials,in the field of HPV,Pneumonia,Rabies,Influenza,COVID-19,Hepatitis,etc.Lianhao Wang received the Bachelor of Medicine in Prevent Medicine from Peking University in 2020 and the Master of Public Health degree in Epidemiology and Health Statistics from Peking University in 2022. His research interests include infectious disease dynamics modeling,clinical trial operations,etc. After graduating,he worked as a clinical research associate at Sinovac Life Sciences Co.,Ltd. He is currently responsible for project management of two clinical trials and has participated in monitoring 5 clinical trials.Hengming Zhang was studied in the Major of Pharmaceutical Engineering at Tianjin University,and obtained master's degree. He is currently serving as the Director of Project Management at Sinovac Biotech Co.,Ltd.,where he is responsible for the management of company's R&D and industrialization projects,and has also participated in the R&D of COVID-19 vaccines.Zhifang Ying,associate technician-in-chief,specializes in quality research and evaluation of poliovirus and COVID-19 related vaccines,as well as clinical serological assessments. She was instrumental in drafting the 2020 edition of the National Pharmaceutical Standards for "Sabin Strain Inactivated Poliovirus Vaccine" in the Chinese Pharmacopoeia,Volume III,along with its explanatory notes. As a sub-project leader,she oversees national key research projects and has significantly contributed to the research of polio-related vaccines and clinical evaluations of COVID-19 vaccines,earning provincial and ministerial level scientific research awards. She has published many academic papers in relevant professional journals,either as the first author or co-first author.Jikai Zhang,Master of Medicine and Chief Physician,has undertaken 17 registered vaccine clinical trial projects as the principal investigator. He has led the establishment of 2 key laboratories under the National Medical Products Administration and 6 research platforms or key laboratories supported by provincial agencies including the Provincial Science and Technology Department,Provincial Development and Reform Commission,Provincial Drug Administration,and Municipal Science and Technology Information Bureau. He has also led 5 provincial and national research projects as the project leader of a partner institution. He has published 44 Chinese and English academic papers as the corresponding author or first author and participated in compiling 7 academic works. Additionally,he has obtained four invention patentxs.
DOI: https://doi.org/10.1080/21645515.2024.2402644
2024-09-25
Human Vaccines & Immunotherapeutics
Abstract:This study aimed to provide evidence for co-administration of the COVID-19 and EV71 vaccines in children aged 3 to 5 years. We conducted a phase 4, open-label, randomized, and controlled study. A total of 520 children were randomly allocated to two groups: Group C received the COVID-19 and EV71 vaccines simultaneously, while Group N received the two vaccines separately. The primary immunogenicity endpoints were the seroconversion rates of anti-SARS-CoV-2 and anti-EV71 antibodies 28 days after the second dose of each respective vaccine. Before vaccination, none of the participants was seropositive for anti-SARS-CoV-2 antibodies, and the baseline seropositivity for anti-EV71 antibodies was low (Group C: 14.86%; Group N: 17.83%). After completing full vaccination, the seroconversion rate of anti-SARS-CoV-2 antibodies reached 100% in both groups, while for anti-EV71 antibodies, the seroconversion rates were 97.99% in Group C and 98.70% in Group N. The lower limit of the 95% confidence interval for the difference in seroconversion rates between the two groups for both COVID-19 and EV71 vaccines met the predefined non-inferiority criteria. Six months post-vaccination, the antibody levels remained high for both vaccines, with the seropositive rates of anti-SARS-CoV-2 antibodies at 91.21% in Group C and 92.77% in Group N, and the seropositive rates of anti-EV71 antibodies at 99.16% in Group C and 99.15% in Group N. Safety analysis revealed a lower incidence of adverse reactions in Group C compared to Group N (28.85% vs 45.56%), primarily solicited. Co-administration of the COVID-19 and EV71 vaccines demonstrated a positive safety profile and non-inferior immune responses.
immunology,biotechnology & applied microbiology